CLDX Celldex Year-over-year net earnings per share growth for the last 12 months
The quarterly EPS trajectory helps assess the Celldex Therapeutics (CLDX) strategy of developing antibodies through partnerships to ensure financial stability. Growing physician demand for new therapies is expanding market reach, while breakthroughs in immunotherapy for skin pathologies secure future revenue. In this context, the 4.70 mark serves as a key metric, allowing analysts to determine the asset's fair value for long-term investment.
Analytical breakdowns and data insights for company Celldex Corp (CLDX)
- market value and analyst target forecast:
- market capitalization data:
- book capitalization indicators:
- debt and liquidity data:
Total Debt to Capital Celldex Therapeutics|CLDX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Celldex Therapeutics|CLDX - Company Cumulative Debt|Debt to Book Capitalization Ratio Celldex|CLDX - Company Long-Term Debt|Company Short-Term Debt Celldex Therapeutics|Quick Ratio celldex.com
- earnings and market multiples details:
CLDX - Company Profit|Projected Future Earnings Celldex Therapeutics|CLDX - Market Cap to Earnings|Projected Price to Earnings Celldex|CLDX - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Celldex|CLDX - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Celldex Therapeutics|CLDX - Earnings per share for the last four quarters|Quarterly EPS earnings growth celldex.com|CLDX - Earnings per share increase in current year|Earnings growth forecast for next year Celldex Therapeutics
Comprehensive company analysis:Celldex Therapeutics
Professional asset selection is based on identifying reversal points of fundamental trends. This metric captures the dynamics of earnings per share, reflecting the impact of the cost of capital on market capitalization. By analyzing the relative quarterly change in EPS, an investor assesses the speed of profitability recovery. For Celldex Therapeutics (CLDX), this indicator is critical due to a high cash burn rate. The success of Barzolvolimab will transform current losses into exponential profit growth.
Direct competitors
argenx (ARGX) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months BioNTech Inc.|Year-over-year net earnings per share growth for the last 12 months ABVX|Quarterly EPS earnings growth ADMA Corp|Year-over-year earnings per share growth for the last twelve months Protagonist Therapeutics (PTGX)|immunovant.com - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth KNSA (Kiniksa)|Grifols SA (GRFS) - Earnings per share growth in annualized terms for the last twelve months|Adaptive Biotechnologies Corp - Quarterly EPS earnings growth|Aurinia Corp (AUPH) - Year-over-year net earnings per share growth for the last 12 months|BCRX: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months veratx.com (VERA)|Year-over-year earnings per share growth for the last twelve months Dianthus Therapeutics, Inc.|Year-over-year earnings per share growth for the last twelve months PHVS|Year-over-year earnings per share growth for the last twelve months AbCellera Corp (ABCL)|Year-over-year earnings per share growth for the last twelve months TRML (Tourmaline)|Quarterly EPS earnings growth PGEN (Precigen, Inc.)|PHAR: Year-over-year earnings per share growth for the last 12 months|Nektar Therapeutics Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Upstream Bio, Inc.|ZBIO (Zenas Biopharma, Inc.) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months IMNM|Year-over-year net earnings per share growth for the last 12 months GOSS|KALV: Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months SEPN (Septerna)|Year-over-year earnings per share growth rate for the last twelve months PVLA|Quarterly EPS earnings growth SVRA (Savara Corp)|Year-over-year earnings per one share growth for the last 12 months RIGL|AnaptysBio, Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months astriatx.com|enGene (ENGN) - Year-over-year earnings per share growth for the last twelve months|rapt.com - Year-over-year earnings per one share growth for the last 12 months|JBIO (Aerovate Therapeutics, Inc.) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Aclaris Therapeutics, Inc|Year-over-year earnings per share growth for the last twelve months Kyverna Therapeutics (KYTX)|TLSA: Year-over-year net earnings per share trend for the last twelve months|Quarterly EPS earnings growth CABA (Cabaletta Bio)|Ventyx Biosciences Inc. (VTYX) - Earnings per share growth in annualized terms for the last twelve months|THTX: Year-over-year net earnings per share growth for the last 12 months|AVTX - Quarterly EPS earnings growth|ELDN (Eledon Pharmaceuticals) - Year-over-year net earnings per share growth for the last 12 months|AGEN: Year-over-year earnings per share growth rate for the last twelve months|CLYM (Climb Bio) - Quarterly EPS earnings growth|zurabio.com (ZURA) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth ATYR|Year-over-year net earnings per share growth for the last 12 months adagene.com ADAG|Year-over-year earnings per share growth for the last twelve months Ikena Oncology IMA|Year-over-year net earnings per share change for the last twelve months Shattuck Labs Inc (STTK)|Equillium Bio - Quarterly EPS earnings growth|Connect Biopharma (CNTB) - Year-over-year net earnings per share growth for the last 12 months|immunic-therapeutics.com (IMUX) - Year-over-year earnings per share growth for the last twelve months|ATRA (Atara Bio) - Year-over-year earnings per share growth for the last twelve months|IFRX (InflaRx NV) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months XFOR (x4pharma.com)|Year-over-year net earnings per share growth for the last 12 months ACET (Adicet Bio)|celularity.com - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months INmune Bio Corp INMB|BRNS (Barinthus Biotherapeutics Corp) - Year-over-year net earnings per share trend for the last twelve months|Kezar Life Sciences - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months SABS (sabbiotherapeutics.com)|AKTX: Quarterly EPS earnings growth|Enlivex Therapeutics Ltd. (ENLV) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Q32 Bio Inc|GOVX: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Edesa Biotech, Inc. (EDSA)|Year-over-year net earnings per share growth for the last 12 months ibioinc.com IBIO|Quarterly EPS earnings growth CARM (Carisma Therapeutics Inc.)|Quarterly EPS earnings growth XTL Biopharmaceuticals Ltd XTLB|BOLT: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months HCWB (HCW Biologics Inc.)|APVO: Quarterly EPS earnings growth|AIM - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Aditxt Inc.|Year-over-year net earnings per share growth for the last 12 months GRI Bio Inc (GRI)|Year-over-year earnings per share growth for the last twelve months XORTX (XRTX)|Year-over-year net earnings per share growth for the last 12 months Vyome Therapeutics HIND|Revelation Biosciences - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth indaptusrx.com INDP|SCNI - Year-over-year earnings per share growth for the last twelve months|CALI (CalciMedica, Inc.) - Year-over-year earnings per share growth for the last 12 months|AFMD: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Allakos (ALLK)|HOOK (HOOKIPA Pharma, Inc.) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months IGM Bio (IGMS)|Quarterly EPS earnings growth ITOS|OCEA - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months TC BioPharm (Holdings) PLC TCBP|Third Harmonic Bio Inc - Year-over-year earnings per share growth for the last twelve months
